Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 12, 2023 11:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
October 11, 2023 07:30 ET
|
Phio Pharmaceuticals Corp.
--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination --Preclinical data demonstrates the effectiveness of...
RNAi Drug Delivery Technologies and Global Market Analysis Report 2023: Historic Market Revenue from 2020 to 2022, Estimates for 2023, and CAGR Projections through to 2028
August 29, 2023 07:08 ET
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNAi Drug Delivery: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global RNAi drug delivery...
RNA Therapy Clinical Trials Market Report 2023-2030: Strategies and Collaborations Shaping the Industry
August 29, 2023 04:48 ET
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report, 2023-2030" report has been added to ResearchAndMarkets.com's offering. ...
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
August 21, 2023 07:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
RNA Therapeutics Markets, 2035 - Technical and Financial Perspective on How the Opportunity in this Domain is Likely to Evolve
April 24, 2023 03:33 ET
|
Research and Markets
Dublin, April 24, 2023 (GLOBE NEWSWIRE) -- The "Investor Series: Opportunities in RNA Therapeutics Market" report has been added to ResearchAndMarkets.com's offering. The Investor Series:...
Global RNA Analysis/Transcriptomics Market Report 2023: Increasing Demand for Personalized Medicine is Expected to Drive Growth
March 31, 2023 07:53 ET
|
Research and Markets
Dublin, March 31, 2023 (GLOBE NEWSWIRE) -- The "RNA Analysis/Transcriptomics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Global RNAi Therapeutics Market 2023 to 2027: Featuring Sanofi, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma and Sirnaomics
March 16, 2023 05:38 ET
|
Research and Markets
Dublin, March 16, 2023 (GLOBE NEWSWIRE) -- The "Global RNAi Therapeutics Market (by Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19...
Biopharmaceuticals Contract Manufacturing Market Research 2023-2030 'Reports Insights'
February 27, 2023 07:00 ET
|
REPORTSINSIGHTS CONSULTING PVT LTD
New York, Feb. 27, 2023 (GLOBE NEWSWIRE) -- The Biopharmaceuticals Contract Manufacturing Market is projected to grow at a CAGR of 5.6% from 2023 to 2030, reaching a value of USD 27.6 Billion by...